Bristol Myers Squibb (CELG-RI) Net Margin Growth (3y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) Net Margin Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -204.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 666.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3,167.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -43,067.00 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 37.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 388.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -15,026.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -6,857.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -1,745.00 |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 706.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 706.00 |
| Mar 31, 2026 | 332.00 |
| Dec 31, 2025 | -907.00 |
| Sep 30, 2025 | 363.00 |
| Jun 30, 2025 | -132.00 |
| Mar 31, 2025 | 1,097.00 |
| Dec 31, 2024 | -1,918.00 |
| Sep 30, 2024 | -313.00 |
| Jun 30, 2024 | 474.00 |
| Mar 31, 2024 | -11,869.00 |
| Dec 31, 2023 | 10,595.00 |
| Sep 30, 2023 | -18.00 |
| Jun 30, 2023 | 1,929.00 |
| Mar 31, 2023 | 2,710.00 |
| Dec 31, 2022 | 3,110.00 |
| Sep 30, 2022 | -841.00 |
| Jun 30, 2022 | -1,092.00 |
| Mar 31, 2022 | -1,795.00 |
| Dec 31, 2021 | 40.00 |
| Sep 30, 2021 | -2,025.00 |